Unicycive Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Shalabh K. Gupta
- Full Time Employees
- 21
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1975 West El Camino Real Mountain View CA United States of America 94040
- IPO Date
- Jul 12, 2021
- CIK
- 0001766140
- Website
- unicycive.com
- Similar Companies
- Business
- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing novel therapies for kidney diseases, including hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis and acute kidney injury (AKI). The company's lead investigational treatment, oxylanthanum carbonate (OLC), is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology that reduces pill burden through smaller, swallowable pills versus chewed alternatives; OLC has received a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025 from the U.S. Food and Drug Administration (FDA), following a Complete Response Letter (CRL) on June 30, 2025, with plans to resubmit the New Drug Application (NDA) by year-end 2025. Its second pipeline candidate, UNI-494, is a novel nicotinamide ester derivative and selective ATP-sensitive mitochondrial potassium channel activator designed to restore mitochondrial function for AKI treatment, potentially addressing an unmet need with no approved therapies currently available. Unicycive Therapeutics maintains license and development agreements with partners including Shilpa Medicare Ltd. for manufacturing and supply of OLC, Sphaera Pharma Pte. Ltd. for UNI-494, Lee's Pharmaceutical (HK) Limited and Lotus International Pte Ltd. for OLC commercialization in select Asian markets such as Mainland China and Hong Kong, and Syneos Health LLC for UNI-494 development support. Recent strategic developments include a $50 million private placement financing in March 2024 led by Octagon Capital and Great Point Partners to advance OLC toward approval and commercialization, a 1:10 reverse stock split effective June 20, 2025 to regain Nasdaq compliance confirmed on July 7, 2025, and RA Capital Management's acquisition of approximately 10 million shares representing a 9.99% stake as of September 30, 2024. The company reported $42.7 million in cash as of September 30, 2025, providing runway into 2027 to support OLC resubmission, potential approval, commercialization preparations, and UNI-494 advancement. Founded in 2016 and headquartered in Los Altos, California, Unicycive Therapeutics targets patients with CKD and AKI primarily in the United States, with strategic partnerships expanding potential access in Asia.
Company News
UNCY INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Unicycive Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm
Law Offices of Howard G. Smith Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders To Inquire About Securities Fraud Class Action
Law Offices of Howard G. Smith Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders To Inquire About Securities Fraud Class Action
Robbins LLP Informs Investors of the Unicycive Therapeutics, Inc. Securities Class Action
Robbins LLP Informs Investors of the Unicycive Therapeutics, Inc. Securities Class Action
UNCY CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit On Behalf Of Unicycive Therapeutics, Inc. Investors
UNCY CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit On Behalf Of Unicycive Therapeutics, Inc. Investors
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.
Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
UNCY SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Unicycive Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Unicycive Stockholders and Encourages Investors to Contact the Firm
UNCY INVESTIGATION ALERT: Investors Who Lost Money in Unicycive Therapeutics, Inc. Should Contact Block & Leviton